All In Biotech

Drug Trial Radar · NCT02121795

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Last checked: Nov 20, 2026Latest source record: Mar 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 668 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

668

Actual

Start

May 6, 2014

Primary completion

Aug 12, 2015

Study completion Mar 1, 2019

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Apr 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of switching from emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) fixed dose combination (FDC) to emtricitabine/tenofovir alafenamide (F/TAF) FDC in HIV-1 positive participants who are virologically suppressed on regimens containing FTC/TDF. This study will consist of a 96 week double-blind treatment period. After Week 96, all participants will continue on blinded study drug treatment and attend visits every 12 weeks until treatment assignments are unblinded. All participants will return for an unblinding visit and will be given the option to receive open-label F/TAF and attend visits every 12 weeks until F/TAF is commercially available, or the sponsor terminates the F/TAF clinical development program.

Conditions

  • HIV-1 Infection

Interventions

  • FTC/TDFDrug

    200/300 mg FDC tablets administered orally once daily

  • F/TAFDrug

    Tablets administered orally once daily

  • Allowed third antiretroviral agentDrug

    An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).

  • FTC/TDF PlaceboDrug

    Tablets administered orally once daily

  • F/TAF PlaceboDrug

    Tablets administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot AnalysisTime frame: Week 48

Locations

78 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Spectrum Medical Group

    Phoenix, Arizona

  • Pacific Oaks Medical Group

    Beverly Hills, California

  • Kaiser Permanente

    Hayward, California

  • Tarrant County ID Associates

    Los Angeles, California

  • Southern California Men's Medical Group

    Los Angeles, California

  • Highland Hospital - Alameda Health System (formerly Alameda County medical Center)

    Oakland, California

  • Kaiser Permanente Sacramento Medical Center

    Sacramento, California

  • La Playa Medical Group and Clinical Research

    San Diego, California

  • Kaiser Permanente Medical Group San Francisco

    San Francisco, California

  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

    Torrance, California

  • Kaiser Permanente Colorado

    Denver, Colorado

  • National Jewish Health

    Denver, Colorado

  • Apex Research LLC

    Denver, Colorado

  • Dupont Circle Physician's Group

    Washington D.C., District of Columbia

  • Whitman-Walker Health

    Washington D.C., District of Columbia

  • Capital Medical Associates

    Washington D.C., District of Columbia

  • Medical Faculty Associates

    Washington D.C., District of Columbia

  • TheraFirst Medical Center

    Fort Lauderdale, Florida

  • Gary J. Richmond,M.D.,P.A.

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • Tarrant County Infectious Disease Associates

    Miami, Florida

  • AIDS Healthcare Foundation

    Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • AIDS Healthcare Foundation

    Tampa, Florida

  • AIDS Research & Treatment Center of the Treasure Coast

    Vero Beach, Florida

  • Triple O Research Institute PA

    West Palm Beach, Florida

  • Atlanta ID Group

    Atlanta, Georgia

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • Mercer University School of Medicine

    Macon, Georgia

  • Community Research Initiative of New England

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Be Well Medical Center

    Berkley, Michigan

  • Hennepin County Medical Center

    Minneapolis, Minnesota

  • The Kc Care Clinic Site 5580

    Kansas City, Missouri

  • St. Louis University

    St Louis, Missouri

  • Southampton Healthcare, Inc.

    St Louis, Missouri

  • Prime Healthcare Services - St Michael's LLC d/b/a Saint Michael's Medical Center

    Newark, New Jersey

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • Southwest CARE Center

    Santa Fe, New Mexico

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.